Antibodies to Interferon-α in Treated Cancer Patients: Incidence and Significance
- 1 March 1997
- journal article
- review article
- Published by Mary Ann Liebert Inc in Journal of Interferon & Cytokine Research
- Vol. 17 (3), 141-143
- https://doi.org/10.1089/jir.1997.17.141
Abstract
Antibodies to interferon-alpha (IFN-alpha) are found in some patients being treated with this cytokine. In studies in which two recombinant IFN-alpha preparations were directly compared in cancer patients, those given IFN-alpha2a were found to have neutralizing antibodies in their serum significantly more often than those given IFN-alpha2b (p <0.001). Patients who develop neutralizing antibodies are more likely to have a clinical relapse and to become resistant to further treatment with at least the IFN preparation initially used for their treatment. In 10 studies in cancer patients, such an outcome was found in 63% of those who developed antibodies but in only 13% of those who did not. These data are tabulated.Keywords
This publication has 14 references indexed in Scilit:
- Roferon (rIFN-α2a) Is More Immunogenic Than Intron A (rIFN-α2b) in Patients with Chronic Myelogenous LeukemiaJournal of Interferon Research, 1994
- Neutralizing Antibodies to Interferon- : Relative Frequency in Patients Treated with Different Interferon PreparationsThe Journal of Infectious Diseases, 1991
- Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infectionHepatology, 1990
- A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis BNew England Journal of Medicine, 1990
- Interferon-induced enhancement of 2',5'-oligoadenylate synthetase in mid-gut carcinoid tumoursThe Lancet, 1990
- Recombinant human interferon (IFN) alpha‐2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti‐interferon antibodiesBritish Journal of Haematology, 1989
- Treatment of Malignant Carcinoid Tumors With Recombinant Interferon alfa-2b: Development of Neutralizing Interferon Antibodies and Possible Loss of Antitumor ActivityJNCI Journal of the National Cancer Institute, 1989
- Resistance to Recombinant Interferon Alfa-2a in Hairy-Cell Leukemia Associated with Neutralizing Anti-Interferon AntibodiesNew England Journal of Medicine, 1988
- Interferons in the Treatment of Human NeoplasmsJournal of Interferon Research, 1987
- CLINICAL SIGNIFICANCE OF ANTI-IFN-α ANTIBODY TITRES DURING INTERFERON THERAPYThe Lancet, 1987